Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2012
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
A T Shaw, A M Varghese, B J Solomon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 30, 2023
Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma
D Boiarsky, C A Lydon, E S Chambers, et al.
ESMO Open
|
September 9, 2022
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
H Park, G I Shapiro, X Gao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2021
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
A J Schoenfeld, S J Antonia, M M Awad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 2024
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
A Di Federico, S L Alden, J W Smithy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 23, 2019
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
E J Aguilar, B Ricciuti, J F Gainor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2025
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancer
B Ricciuti, S Scalera, X Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 17, 2021
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy
A Cortellini, B Ricciuti, F Facchinetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
J K Sabari, G C Leonardi, C A Shu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50
J F Gainor, H Rizvi, E Jimenez Aguilar, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2012
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
A T Shaw, A M Varghese, B J Solomon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 30, 2023
Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma
D Boiarsky, C A Lydon, E S Chambers, et al.
ESMO Open
|
September 9, 2022
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
H Park, G I Shapiro, X Gao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2021
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
A J Schoenfeld, S J Antonia, M M Awad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 2024
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
A Di Federico, S L Alden, J W Smithy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 23, 2019
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
E J Aguilar, B Ricciuti, J F Gainor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2025
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancer
B Ricciuti, S Scalera, X Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 17, 2021
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy
A Cortellini, B Ricciuti, F Facchinetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
J K Sabari, G C Leonardi, C A Shu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50
J F Gainor, H Rizvi, E Jimenez Aguilar, et al.
Page
of 5